AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

D D Gladman,M Strauss,C Han,A Andrew Östör,M Starr,M Shawi,P J Mease,R Ranza,E Rampakakis,A M Bravo Perdomo

doi:10.1136/annrheumdis-2023-eular.1918

AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

D D Gladman, M Strauss + Show 8 more

Open Access

PDF Available

https://doi.org/10.1136/annrheumdis-2023-eular.1918

Copy DOI

Export

Save

Cite

Journal: Annals of the Rheumatic Diseases

Publication Date: May 30, 2023

Affiliation: Janssen (United States), Monash University, Montreal General Hospital, Johnson & Johnson (United States), Universidade Federal de Uberlândia

#Functional Assessment Of Chronic Illness Therapy – Fatigue #Functional Assessment Of Chronic Illness Therapy – Fatigue Score #Guselkumab #Meaningful Improvements In Fatigue #Baseline #Proportions Of Pts #Assessment Of Chronic Illness Therapy #Normative Levels #Minimal Disease Activity #Treatment Group

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

BackgroundThe IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment[1] independent of its effects on American College of Rheumatology 20% (ACR20) improvement criteria and...

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

AB1087 LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS